Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
Genom att skicka in godkänner du våra Användarvillkor
105635 trials found · Page 1 of 5282
-
Landmark trial proves mRNA vaccine stops COVID-19
⭐️ VACCINE ⭐️ CompletedThis is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals. The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expand…
Phase: PHASE2, PHASE3 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 18, 2026 11:47 UTC
-
Silence no more: gene therapy aims to cure deafness in kids
⭐️ CURE ⭐️ Recruiting nowThis study is a multicenter, single-arm, open-label Phase I/II clinical trial, which is designed to evaluate the safety, tolerability and efficacy of EHT102 injection in treating congenital hearing loss secondary to biallelic mutations of OTOF (DFNB9).Up to 30 pediatric participa…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Euhearing Therapeutics Co., Ltd • Aim: ⭐️ CURE ⭐️
Last updated Jun 08, 2026 13:08 UTC
-
Gene therapy offers hope for babies with 'Bubble Boy' disease
⭐️ CURE ⭐️ Recruiting nowThe purpose of this study is to evaluate the Safety and Efficacy of Gene Therapy of the severe combined immunodeficiency (SCID) caused by mutations in the human DCLRE1C gene (Artemis) by transplantation of a single dose of autologous CD34+ cells transduced ex vivo with the G2ARTE…
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: ⭐️ CURE ⭐️
Last updated Jun 15, 2026 19:07 UTC
-
CRISPR stem cell therapy could end transfusions for sickle cell and thalassemia patients
Disease control Recruiting nowThis is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSP…
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
Major malaria vaccine trial could save thousands of children
⭐️ VACCINE ⭐️ OngoingA Phase III randomized controlled multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria
Phase: PHASE3 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 22, 2026 12:04 UTC
-
Oxford vaccine trial shows promise against COVID-19
⭐️ VACCINE ⭐️ CompletedA phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.
Phase: PHASE2, PHASE3 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 15, 2026 19:05 UTC
-
Oxford COVID-19 vaccine shows promise in early trial
⭐️ VACCINE ⭐️ CompletedA phase I/II single-blinded, randomised, multi-centre study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers aged 18-55 years. The vaccine will be administered intramuscularly (…
Phase: PHASE1, PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 22, 2026 12:06 UTC
-
One-Time gene therapy helps babies with fatal muscle disease sit independently
Disease control CompletedPhase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi (gene replacement therapy) in patients with spinal muscular atrophy (SMA) Type 1 who meet enrollment criteria and are genetically defined by a biallelic pathogenic mutation of the survival motor …
Phase: PHASE3 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated Jun 08, 2026 13:17 UTC
-
Gene therapy aims to cure 'bubble boy' disease in young children
⭐️ CURE ⭐️ Recruiting nowThis is a phase I/II open label multi-center study in which patients will receive low dose targeted busulfan followed by infusion of autologous CD34+ selected bone marrow or mobilized peripheral blood cells transduced with the G2SCID vector. Subjects will be enrolled over 3 years…
Phase: PHASE1, PHASE2 • Sponsor: David Williams • Aim: ⭐️ CURE ⭐️
Last updated Jun 22, 2026 12:06 UTC
-
One-Time gene therapy helps babies with rare muscle disease sit and survive
Disease control CompletedPhase 3 pivotal US trial studying open-label intravenous administration of onasemnogene abeparvovec-xioi in spinal muscular atrophy (SMA) Type 1 participants.
Phase: PHASE3 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
Could Lab-Grown nerve cells help paralyzed patients move again?
Disease control Not yet recruitingPurpose: This clinical trial is studying an investigational cell therapy called XS228-a lab-made stem cell product designed to help repair damaged nerves in the spinal cord. The goal is to see if XS228 is safe and can improve movement, sensation, and function in people with recen…
Phase: PHASE2 • Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 17, 2026 12:05 UTC
-
3-Day malaria cure could transform treatment
⭐️ CURE ⭐️ Not yet recruitingCurrent treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes, but this needs to be balanced against increased risk of side effects. Recent data from a trial in children in Papua New Guinea (PNG) suggests a …
Phase: PHASE3 • Sponsor: Menzies School of Health Research • Aim: ⭐️ CURE ⭐️
Last updated Jun 12, 2026 12:04 UTC
-
Engineered immune cells take on Hard-to-Treat scleroderma in landmark trial
Disease control Recruiting nowThe purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis
Phase: PHASE3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
Could a single gene therapy injection restore hearing in deaf children?
⭐️ CURE ⭐️ Recruiting nowSkylark Bio is conducting a study of an investigational new drug called SKY-GJB2 and its delivery device, the SKY-CAT. SKY-GJB2 is a gene therapy that is being developed to treat children who have hearing loss due to changes in the GJB2 gene (also referred to as Connexin 26). The…
Phase: PHASE1, PHASE2 • Sponsor: Skylark Bio Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jun 16, 2026 12:51 UTC
-
Gene editing trial hopes to fix duchenne muscular dystrophy at its source
Disease control Recruiting nowThe purpose of this Phase 1/2a trial is to evaluate the safety, tolerability, and preliminary efficacy of PBGENE-DMD in patients with DMD harboring mutations amenable to excision of exons 45-55. Given the limitations of existing therapeutic strategies, PBGENE-DMD represents a nov…
Phase: PHASE1, PHASE2 • Sponsor: Precision BioSciences, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Hope for kids with rare paralysis: gene therapy trial launches
Disease control Recruiting nowPhase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Paraplegia Type 50 (SPG50).
Phase: PHASE3 • Sponsor: Elpida Therapeutics SPC • Aim: Disease control
Last updated Jun 08, 2026 13:08 UTC
-
Could a smart blood test guide breast cancer patients to a cure?
⭐️ CURE ⭐️ Recruiting nowThie purpose of this study is to find out whether a personalized treatment approach-using a series of ctDNA tests along with standard imaging scans to help decide when to step up (escalate) or decrease (de-escalate) sequential treatments (given one after another)-combined with lo…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated Jun 15, 2026 18:56 UTC
-
UCLA tests stem cell trick to free liver patients from lifelong pills
Disease control Recruiting nowThis clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed…
Phase: PHASE1, PHASE2 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
Radical new schedule aims to cure High-Risk ewing sarcoma
⭐️ CURE ⭐️ Recruiting nowThis single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that apply to species and population dynamics a…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: ⭐️ CURE ⭐️
Last updated Jun 17, 2026 12:08 UTC
-
Could a two-drug combo cure hepatitis b in kids?
⭐️ CURE ⭐️ Not yet recruitingThis study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-active, HBeAg-positive children aged 3-6 years with chronic hepatitis B.
Phase: PHASE4 • Sponsor: Qing-Lei Zeng • Aim: ⭐️ CURE ⭐️
Last updated Jun 16, 2026 12:52 UTC